首页> 美国政府科技报告 >Effects of Oral Tag 1-MeATN02 (TRIAMINOGUANIDINIUM-1-METHYL-5- NITRIMINOTETRAZOLATE-TAG-MNT/K-26) Exposure to Female Rats (RATTUS NORVEGICUS) TAG-MNT/K-26 Exposure to Female Rats (Rattus norvegicus)
【24h】

Effects of Oral Tag 1-MeATN02 (TRIAMINOGUANIDINIUM-1-METHYL-5- NITRIMINOTETRAZOLATE-TAG-MNT/K-26) Exposure to Female Rats (RATTUS NORVEGICUS) TAG-MNT/K-26 Exposure to Female Rats (Rattus norvegicus)

机译:口服标签1-meaTN02(三亚胍基-1-甲基-5-硝基氨基偶氮唑 - TaG-mNT / K-26)暴露于雌性大鼠(RaTTUs NORVEGICUs)TaG-mNT / K-26暴露于雌性大鼠(褐家鼠)的影响

获取原文

摘要

The objective of this research is to determine the oral LD50 of Triaminoguanidinium- 1-methyl-5nitriminotetrazolate (TAG-MNT), and to determine if adverse effects occur fom a 14-day repetitive oral exposure regime of TAG- MNT in the female rat, i.e., derive the no-observable-effect-level (NOAEL) and lowest-observed-effect-level (LOAEL). TAG-MNT is not acutely toxic at the limit dose, but as early as 14-days of daily oral exposure caused liver toxicity and death. The primary target organ is the liver; TAG-MNT causes centrilobular hypertrophy, vacuolization and increased liver weight. In the higher dose groups liver pathology is correlated with decreased food consumption, body weight loss, and death. The LOAEL from oral exposure to TAG-MNT for 14-days, as determined from this study, is 50 mg/kg-day based on significant adverse event of increased kidney and liver weight ratios and adverse histological alterations in the liver. The NOAEL is therefore determined to be 250 mg/kg-d where only mild adaptive hepatic vacuolization was observed in a subset of exposed individuals.

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号